Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Alectinib (Alecensaro) for Non-Small Cell Lung Cancer (first line)
(Notification to Implement Issued Issued as of August 10, 2018)

Blinatumomab (Blincyto) for Philadelphia Chromosome Positive B-cell Precursor Acute Lymphoblastic Leukemia
(Pending Submission as of August 2, 2018)

Lutetium Lu 177 dotatate (Lutathera) for Gastroenteropancreatic Neuroendocrine Tumors
(Open for Input on Submission until August 14, 2018)

Brentuximab Vedotin (Adcetris) for Hodgkin Lymphoma Resubmission
(Pending Submission as of July 26, 2018)

Nivolumab (Opdivo) for Melanoma Adjuvant Therapy 
(Pending Submission as of July 26, 2018)


Find a Drug Review